(Q50652493)

English

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

scientific article published on 22 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. (English)

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

0 references

0 references

cannabinoid receptor

0 references

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

15

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

author name string

Mark D Black

1

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Rachel J Stevens

2

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Nancy Rogacki

3

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Robert E Featherstone

4

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Yaw Senyah

5

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Odessa Giardino

6

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Beth Borowsky

7

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Jeanne Stemmelin

8

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Caroline Cohen

9

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Philippe Pichat

10

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Michal Arad

11

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Amaya De Levie

13

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Ina Weiner

14

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

Geoffrey B Varty

16

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

publication date

22 December 2010

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

number of pages

15

1 reference

based on heuristic

inferred from page(s)

Psychopharmacology

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

215

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

1

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

149-163

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

https://scigraph.springernature.com/pub.10.1007/s00213-010-2124-0

0 references

Marijuana and Memory

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Advancing a neurodevelopmental origin for schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Recent advances in the neuropathology of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Endocannabinoid control of food intake and energy balance

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Nitric oxide: a novel link between synaptic and nonsynaptic transmission

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Construct Validity of the Animal Latent Inhibition Model of Selective Attention Deficits in Schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Involvement of CB1 cannabinoid receptors in emotional behaviour.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

The endocannabinoid nervous system: unique opportunities for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Nitric oxide synthase inhibition during synaptic maturation decreases synapsin I immunoreactivity in rat brain.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Implications of normal brain development for the pathogenesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

GDNF and BDNF alter the expression of neuronal NOS, c-Jun, and p75 and prevent motoneuron death following spinal root avulsion in adult rats.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2124-0

21 January 2018

Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of pharmacology to side effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Roles of NMDA receptor activity and nitric oxide production in brain development

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Behavioural Validation of a Light/Dark Choice Procedure for Testing Anti-Anxiety Agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Locomotor behavior.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antipsychotic-induced weight gain: a review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nitric oxide mediates the formation of synaptic connections in developing and regenerating olfactory receptor neurons

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoid pharmacology: the first 66 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/21181124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-010-2124-0

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/21181124

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50652493&oldid=1786137657"